(:DRNA)

Dec 28, 2021 09:04 am ET
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.
Dec 25, 2021 08:00 am ET
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.
Dec 14, 2021 04:55 pm ET
DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA
NEW ORLEANS, Dec. 14, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dicerna Pharmaceuticals, Inc. (NasdaqGS: DRNA) to Novo Nordisk A/S (NYSE: NVO).  Under the terms of the proposed transaction, shareholders of Dicerna will receive $38.25 in cash for each share of Dicerna that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 09, 2021 01:18 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - ROG, PAE, MNTV, CSPR, VLY, DRNA
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 09, 2021 07:41 am ET
Direxion Launches mRNA ETF (MSGR)
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology.
Dec 04, 2021 10:16 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADTN, ROG, VG, DRNA; Shareholders are Encouraged to Contact the Firm
NEW YORK, Dec. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 02, 2021 07:12 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds STXB, DRNA, DVD and VSAT Shareholders About Its Ongoing Investigations
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
Dec 02, 2021 11:47 am ET
Moore Kuehn Encourages ASPC, ROG, DRNA, and VG Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Nov 26, 2021 08:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CONE, VLY, DRNA, CSPR; Shareholders are Encouraged to Contact the Firm
NEW YORK, Nov. 26, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Nov 22, 2021 03:38 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dicerna Pharmaceuticals, Inc. - DRNA
NEW YORK, Nov. 22, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Dicerna Pharmaceuticals, Inc. ("DRNA" or the "Company") (DRNA) relating to its proposed acquisition by Novo Nordisk. Under the terms of the agreement, DRNA shareholders will receive $38.25 in cash per share they own.
Nov 20, 2021 02:05 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COR, DRNA, STXB, BCML; Shareholders are Encouraged to Contact the Firm
NEW YORK, Nov. 20, 2021 /PRNewswire/ --Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Nov 19, 2021 10:15 pm ET
DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA
NEW ORLEANS, Nov. 19, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dicerna Pharmaceuticals, Inc. (NasdaqGS: DRNA) to Novo Nordisk A/S (NYSE: NVO).  Under the terms of the proposed transaction, shareholders of Dicerna will receive $38.25 in cash for each share of Dicerna that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Nov 18, 2021 07:58 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.
NEW YORK, Nov. 18, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (NASDAQ: DRNA) in connection with the proposed acquisition of the Company by Novo Nordisk. Under the terms of the merger agreement, the Company's shareholders will receive $38.25 per share in cash for each share of Dicerna common stock that they hold. The all-cash transaction is valued at $3.3 billion.
Nov 18, 2021 02:55 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Dicerna Pharmaceuticals, Inc.
Rigrodsky Law, P.A. announces that it is investigating Dicerna Pharmaceuticals, Inc. (“Dicerna”) (NASDAQ GS: DRNA) regarding possible breaches of fiduciary duties and other violations of law related to Dicerna’s agreement to be acquired by Novo...
Nov 18, 2021 02:16 pm ET
DICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) breached their fiduciary duties or violated the...
Nov 18, 2021 01:33 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates DRNA, RC, HFC, EBMT; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Nov 18, 2021 10:37 am ET
Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DR
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders.
Nov 18, 2021 09:58 am ET
Shareholder Alert: Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtained a Fair Price in its going private transaction with Novo Nordisk
MILWAUKEE, Nov. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating Dicerna (Nasdaq: DRNA), for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. 
Nov 18, 2021 07:30 am ET
Thinking about buying stock in Dicerna Pharmaceuticals, Cloopen Group, Calithera Biosciences, ZTO Express, or Macy's?
NEW YORK, Nov. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRNA, RAAS, CALA, ZTO, and M.
Nov 18, 2021 07:00 am ET
Novo Nordisk to Acquire Dicerna
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which rep
Nov 12, 2021 08:10 am ET
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company (“Lilly”) has declared proof of principle for the first two targets in the companies’ exclusive relationship in neurodegeneration and pain, under the companies’ g
Nov 12, 2021 08:00 am ET
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled, randomized trial of belcesiran, an investigational GalXC™ RNAi therapeutic in development for the treatment of alpha-1 antitrypsin
Nov 09, 2021 07:30 am ET
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update.
Nov 04, 2021 01:15 pm ET
 Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced results of the PHYOX™2 pivotal clinical trial of nedosiran, an investigational GalXC™ RNAi candidate for the treatment of primary hyperoxaluria (PH), in a late-breaker poster presentation a
Nov 02, 2021 04:05 pm ET
Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021.
Oct 19, 2021 07:30 am ET
Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced top-line results from its PHYOX4 study designed to evaluate the safety and tolerability of a single subcutaneous dose of nedosiran, Dicerna’s late-stage investigational GalXC™ RNAi therapeu
Oct 15, 2021 04:01 pm ET
Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced an abstract on clinical data from the Company’s PHYOX™2 trial of nedosiran, an investigational GalXC™ RNAi candidate for the treatment of primary hyperoxaluria (PH), has been accepted as a
Oct 14, 2021 04:54 pm ET
Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that two abstracts related to the Company’s clinical development programs have been accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) The
Oct 01, 2021 04:38 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 61,350 shares of common s
Sep 28, 2021 07:30 am ET
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD, Dicerna’s investigational GalXC™ RNAi therapeutic in development for the treatment of alcohol use disorder
Sep 22, 2021 07:30 am ET
Dicerna Announces New Executive Leadership Appointments
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Rob Ciappenelli as Chief Strategy Officer, the promotion of Marc Abrams, Ph.D., to Senior Vice President, Discovery Research and the addition
Sep 02, 2021 04:05 pm ET
Dicerna to Participate in 16th Annual Citi Biopharma Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 16th Annual Citi Biopharm
Aug 09, 2021 07:00 am ET
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the quarter ended June 30, 2021 and provided a corporate update.
Aug 05, 2021 04:01 pm ET
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced positive top-line results from the Company’s PHYOX™2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hypero
Aug 02, 2021 04:05 pm ET
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021.
Jul 29, 2021 07:30 am ET
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (IND) application for DCR-AUD, the Company’s investigational RNAi candidate
Jul 21, 2021 08:00 am ET
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced interim results from the four completed active-treatment dose cohorts (0.1, 1.0, 3.0 and 6.0 mg/kg) of its Phase 1 double-blind, placebo-controlle
Jul 01, 2021 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common s
Jun 22, 2021 07:30 am ET
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced it has initiated patient dosing in the Company’s Phase 2 ESTRELLA trial of belcesiran, an investigational GalXC™ RNAi therapeutic candidate for the treatment of alpha
Jun 16, 2021 07:30 am ET
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced it has completed dosing in the Company’s PHYOX™4 single-dose safety and tolerability study of its investigational candidate, nedosiran, for the treatment of pri
Jun 03, 2021 04:05 pm ET
Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs
May 27, 2021 07:30 am ET
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (“FDA”) acceptance of the Investigational New Drug (“IND”) application filed by
May 24, 2021 07:30 am ET
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that
May 12, 2021 04:05 pm ET
Dicerna to Participate in Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences:
May 06, 2021 04:05 pm ET
Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Apr 29, 2021 04:05 pm ET
Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2021 financial results after market close on Thursday, May 6, 2021.
Apr 08, 2021 07:40 am ET
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180...
Apr 08, 2021 07:30 am ET
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc
Apr 01, 2021 04:45 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common s
Mar 30, 2021 10:50 am ET
Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown ag
Mar 24, 2021 07:30 am ET
Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna, will present new nonclinical data discussing the Company’s GalXC-Plus™ RNAi technolo
Mar 11, 2021 07:30 am ET
Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will host a webinar on its recently announced alcohol use disorder (AUD) candidate, DCR-AUD. The event will take place on March 18, 2021 at 4:3
Mar 04, 2021 07:30 am ET
Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that Roche has initiated RG6346 in a Roche-sponsored Phase 2 combination trial for the treatment of chronic hepatitis B virus (HBV) infection. RG6346 is an inve
Feb 25, 2021 04:05 pm ET
Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.
Feb 18, 2021 04:05 pm ET
Dicerna to Participate in Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences:
Feb 18, 2021 07:30 am ET
Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its financial results for the full year ended Dec. 31, 2020 after market close on Thursday, Feb. 25, 2021.
Feb 11, 2021 07:30 am ET
Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced initiation of patient dosing in the Company’s PHYOX™4 clinical trial to assess its lead investigational candidate, nedosiran, for the treatment of pr
Jan 05, 2021 04:05 pm ET
Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in two events at the H.C. Wainwright Virtual BioConnect Conference tak
Jan 05, 2021 07:30 am ET
Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced Novo Nordisk A/S (“Novo”) has nominated its first candidate under the existing agreement between the two companies for the discovery and development of novel th
Jan 04, 2021 05:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 23,350 shares of common s
Jan 04, 2021 07:30 am ET
Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced enrollment completion in the Company’s PHYOX™2 pivotal, double-blind, randomized, placebo-controlled clinical trial of its lead investigational therapy, nedosir
Dec 01, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common s
Nov 16, 2020 07:31 am ET
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced positive updated data from its Phase 1 double-blind, placebo-controlled, proof-of-concept trial of RG6346, an investigational GalXC™ RNAi therapeutic that Dicer
Nov 16, 2020 07:30 am ET
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (“RNAi”) therapeutics, today announced U.S. Food and Drug Administration (“FDA”) acceptance of the Investigational New Drug Application (“IND”) filed by Eli Lilly and Company (“Lilly”) for LY35617
Nov 11, 2020 04:05 pm ET
Dicerna to Participate in Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will be participating in fireside chats at two upcoming investor conferences:
Nov 10, 2020 04:05 pm ET
Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Marc Abrams, Ph.D., vice president of discovery research, will present an update on the Company’s early-stage development of extrahepatic RNAi therapeutics
Nov 05, 2020 04:05 pm ET
Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended Sept. 30, 2020.
Nov 02, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 40,950 shares of common s
Nov 01, 2020 12:00 pm ET
Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD’s The Liver Meeting® Digital Experience™ 2020
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that updated data related to RG6346, an investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection, will be presente
Oct 29, 2020 04:05 pm ET
Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that the Company will release its third quarter 2020 financial results after market close on Thursday, Nov. 5, 2020.
Oct 22, 2020 10:05 am ET
Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced positive new interim data from its ongoing PHYOX™3 open-label trial of once-monthly nedosiran, an investigational candidate in development for the treatment of
Oct 13, 2020 04:05 pm ET
Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference
Oct 13, 2020 07:00 am ET
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
VBL Therapeutics (Nasdaq: VBLT) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to becoming Chairman during 2021, at which time Bennett Shapiro, M.D., the current Chairman of the Board, will...
Oct 09, 2020 04:05 pm ET
Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that clinical data on nedosiran, an investigational candidate for the treatment of primary hyperoxaluria (PH), will be presented during the American Society of
Oct 01, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 288,525 shares of common
Sep 28, 2020 04:05 pm ET
Dicerna to Participate in the Chardan 4th Annual Genetic Medicines Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Mon
Sep 16, 2020 07:30 am ET
Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary
“Ling is a proven legal expert with deep and diverse biopharma experience, from research through global commercialization, and we welcome her to our management team,” said Douglas Fambrough, Ph.D., president and chief executive officer of Dicerna. “Ling’s significant knowledge of global drug development, combined with her extensive strategic alliance and corporate governance experience, will be especially valuable as we continue to advance core and collaborative discovery and development programs and evolve as a company into a fully integrated commercial-stage organization.
Sep 02, 2020 04:05 pm ET
Dicerna to Participate in Upcoming September Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be participating in three virtual investor conferences in September:
Sep 01, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 146,450 shares of common
Aug 06, 2020 07:01 am ET
Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Techno
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced positive data from its Phase 1 proof-of-concept trial of RG6346, an investigational candidate for the treatment of chronic hepatitis B virus (HBV) infection in
Aug 06, 2020 07:00 am ET
Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the second quarter ended June 30, 2020.
Aug 05, 2020 04:05 pm ET
Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Shreeram Aradhye, M.D., will become Dicerna’s executive vice president and chief medical officer (CMO) and a member of the Company’s executive leadership te
Aug 03, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 75,100 shares of common s
Jul 01, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 165,800 shares of common
Jun 18, 2020 07:30 am ET
Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (“FDA” or the “agency”) has granted rare pediatric disease designation for nedosiran, an investigational RNAi therapy
Jun 01, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 228,175 shares of common
May 26, 2020 04:05 pm ET
Dicerna to Participate in Jefferies Virtual Global Healthcare Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview as part of the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020
May 12, 2020 04:05 pm ET
Dicerna to Present at Upcoming May Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following conferences being held virtually:
May 07, 2020 04:05 pm ET
Dicerna Announces First Quarter 2020 Financial Results and Provides a Business Update
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the first quarter ended March 31, 2020.
May 07, 2020 04:01 pm ET
Dicerna Announces Appointment of Douglas Pagán as Chief Financial Officer
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas Pagán will become Dicerna’s chief financial officer (CFO) and a member of the Company’s executive leadership team, effective May 26, 2020. Dicerna p
May 01, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 196,450 shares of common
Apr 30, 2020 04:05 pm ET
Dicerna to Report First Quarter 2020 Financial Results on May 7, 2020
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2020 financial results after market close on Thursday, May 7, 2020.
Apr 01, 2020 04:30 pm ET
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 136,300 shares of common
Mar 31, 2020 07:30 am ET
Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today provided an overview of initial observations from the PHYOX™3 long-term, multidose, open-label rollover extension trial evaluating nedosiran, the Company’s lead product candidate in develop
Mar 26, 2020 04:05 pm ET
Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today provided an overview of its response to the COVID-19 pandemic and an update on business continuity and clinical development milestones. Dicerna has been closely monitoring the rapidly evolvi
Mar 18, 2020 04:05 pm ET
Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Dicerna’s DCR-A1AT for the treatment of alpha-1 antitrypsin (A1AT)
Mar 02, 2020 04:30 pm ET
Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 152,400 sha
Feb 27, 2020 04:05 pm ET
Dicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial results for the fourth quarter and full year ended Dec. 31, 2019, and provided a corporate update.
Feb 20, 2020 04:05 pm ET
Dicerna™ to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2019 financial results after market close on Thursday, Feb. 27, 2020.
Feb 18, 2020 04:05 pm ET
Dicerna™ to Present at Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at two upcoming investor conferences:
Feb 10, 2020 07:30 am ET
Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Stephen Doberstein, Ph.D., Chief Scientific Fellow at Nektar Therapeutics, Inc. (“Nektar”), to Dicerna’s board of directors (the
Feb 03, 2020 04:30 pm ET
Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 159,700 sha
Jan 02, 2020 04:30 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 18
Jan 02, 2020 07:30 am ET
Dicerna™ Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the discovery and development agreement between Dicerna and Novo Nordisk A/S (Novo Nordisk) following expiration of the waiting peri
Dec 19, 2019 07:30 am ET
Dicerna™ Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the successful closing of the research collaboration and licensing agreement between Dicerna and Roche following expiration of the waiting period u
Dec 17, 2019 07:30 am ET
Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has granted orphan drug designation to Dicerna’s DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1
Dec 16, 2019 08:00 am ET
Dec 02, 2019 04:30 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 178
Nov 26, 2019 04:05 pm ET
Dicerna™ to Present at Evercore ISI 2nd Annual HealthCONx Conference
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Evercore ISI 2nd Annual HealthCONx Conf
Nov 18, 2019 06:00 am ET
Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) and Novo Nordisk A/S today announced an agreement to discov
Nov 13, 2019 04:05 pm ET
Dicerna™ to Present at the Stifel 2019 Healthcare Conference
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 a
Nov 07, 2019 04:05 pm ET
Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate update.
Nov 04, 2019 07:30 am ET
Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2019 financial results after market close on Thursday, November 7, 2019.
Nov 01, 2019 08:06 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 209,500 shares of common stock to be
Oct 31, 2019 06:30 am ET
Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to develop novel therapies for the treatment of chronic hepatitis B virus (HBV) infection using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration will focus on worldwide
Oct 01, 2019 04:30 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 229,000 shares of common stock to be
Sep 25, 2019 04:05 pm ET
 Dicerna™ to Present at Two Upcoming Investor Conferences
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that management will present at two investor conferences in October.
Sep 19, 2019 04:05 pm ET
Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Patrick Gray to the Dicerna board of directors (the “board”) as an independent director, and the retirement of veteran director Dennis Langer, M.D., J.D. Mr. Gray will serv
Sep 04, 2019 04:05 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 29,000 shares of common stock to be
Sep 03, 2019 04:05 pm ET
Dicerna™ to Present at H.C. Wainwright 21st Annual Global Investment Conference
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conferenc
Aug 08, 2019 04:05 pm ET
Dicerna™ Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial results for the second quarter ended June 30, 2019 and provided a corporate update.
Aug 02, 2019 04:05 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 218,500 shares of common stock to be
Aug 01, 2019 04:05 pm ET
Dicerna™ to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2019 financial results after market close on Thursday, August 8, 2019.
Jul 15, 2019 07:30 am ET
Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1)
DicernaTM Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to DCR-PHXC for the treatment of patients with primary hyperoxaluria type 1 (
Jul 02, 2019 07:00 am ET
Dicerna™ to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
DicernaTM Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced it submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA) last week to conduct a first-in-human Phase 1/2 study of DCR-A1AT, an in
Jul 01, 2019 04:30 pm ET
Dicerna™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 529,500 shares of common stock to be
Jun 21, 2019 07:30 am ET
Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
DicernaTM Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced updated data from its ongoing PHYOX™1 Phase 1 clinical trial evaluating DCR-PHXC, the Company’s lead GalXC™ product candidate. Investigators reported additional results evaluating
Jun 20, 2019 07:30 am ET
Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria
“Dicerna is delighted to welcome one of the world’s leading pediatric nephrologists to our team,” said Douglas M. Fambrough, Ph.D., president and chief executive officer of Dicerna. “We are privileged that Dr. Hoppe has chosen to apply his deep clinical and scientific knowledge of primary hyperoxaluria to the development of DCR-PHXC, our lead product candidate and the only RNAi-based therapy designed to treat all genetic types of primary hyperoxaluria.”
Jun 13, 2019 07:30 am ET
Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Steven A. Kates, Ph.D., as vice president, regulatory affairs, and of David J. Caponera as head of patient adv
Jun 04, 2019 07:30 am ET
Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Rob Ciappenelli as chief commercial officer of Dicerna and member of the Company’s executive leadership team, e
Jun 03, 2019 04:30 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 230
May 28, 2019 04:05 pm ET
Dicerna™ to Present at the Jefferies 2019 Healthcare Conference
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate update at the Jefferies 201
May 16, 2019 07:30 am ET
Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the dosing of the first patient in its Phase 1 clinical trial of DCR-HBVS, the Company’s investigational GalXCTM-based therapy f
May 09, 2019 04:05 pm ET
Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the first quarter ended March 31, 2019.
May 03, 2019 04:05 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 145
May 02, 2019 04:05 pm ET
Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2019 financial results after market close on Thursday, May 9, 2019.
May 02, 2019 07:30 am ET
Dicerna™ Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX™2 Pivotal Trial
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the submission of an updated investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for DCR-PH
Apr 01, 2019 04:30 pm ET
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 282
Apr 01, 2019 04:05 pm ET
Dicerna™ to Present at the H.C. Wainwright Global Life Sciences Conference
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate update at the H.C. Wainwright G
Mar 29, 2019 06:30 am ET
Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), (the “Company” or “Dicerna”) a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the presentation of updated data from its ongoing PHYOX™1 Phase 1 clinical trial evaluating DCR-PHXC, the Company’s lead GalXC™
Mar 11, 2019 04:05 pm ET
Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter and year ended December 31, 2018.
Mar 06, 2019 08:30 am ET
New Research: Key Drivers of Growth for Energy Transfer LP, Domo, Accenture, Chevron, Cincinnati Financial, and Dicerna Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Producti
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Energy Transfer LP (NYSE:ET), Domo, Inc. (NASDAQ:DOMO), Accenture PLC...
Mar 04, 2019 04:05 pm ET
Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and year end 2018 financial results after market close on Monday, March 11, 2019.
Mar 01, 2019 04:30 pm ET
Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 238,000 shares of common st
Feb 22, 2019 04:49 pm ET
Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March:
Feb 21, 2019 09:10 am ET
ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the addition of three industry veterans to the Company’s management team:
Feb 12, 2019 12:17 pm ET
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs successfully to patients.
Feb 12, 2019 12:17 pm ET
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs successfully to patients.
Feb 05, 2019 07:35 am ET
Recent Analysis Shows DICK'S Sporting Goods, Zix, Q2, InfraREIT, The Boston Beer, and Dicerna Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DICK'S Sporting Goods, Inc. (NYSE:DKS), Zix Corporation (NASDAQ:ZIXI), Q2...
Feb 01, 2019 04:30 pm ET
Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 419,000 shares of common s
Jan 28, 2019 07:30 am ET
Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the “Company”) a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human volunteer in its Phase 1 clinical trial of DCR-HBVS, the Company’s investigational GalXCTM-based therapy for the treatment of chronic hepati
Jan 24, 2019 07:30 am ET
Dicerna Evolves Its Board of Directors to Support Continued Growth
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced several changes to its board of directors (BOD), including the elevation of J. Kevin Buchi to chairman of the board; the appointment of industry experts Marc Kozin, pro
Jan 08, 2019 04:05 pm ET
Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 182,0
Jan 04, 2019 07:00 am ET
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna
Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of in
Dec 19, 2018 04:34 pm ET
Dicerna to Join NASDAQ Biotechnology Index
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) as part of the annual re-ranking, which will become effective prior to market open on Monday, December 24, 2018.
Dec 19, 2018 07:30 am ET
Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and Company following clearance under the Hart-Scott Rodino Antitrust Impro
Nov 30, 2018 07:45 am ET
Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Resul
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), Sun Life Financial Inc....
Nov 29, 2018 07:30 am ET
Dicerna to Participate in Citi’s 2018 Global Healthcare Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will host one-on-one investor meetings at Citi’s 2018 Global Healthcare Conference at the Lott
Nov 09, 2018 08:00 am ET
Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, will host an R&D Day today in New York City to discuss its pipeline of GalXC™-based RNAi therapeutic candidates.
Nov 06, 2018 07:30 am ET
Dicerna to Participate in Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November.
Nov 05, 2018 04:05 pm ET
Dicerna Reports Third Quarter 2018 Financial and Operating Results and Provides Corporate Update
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the third quarter ended September 30, 2018.
Oct 30, 2018 07:30 am ET
Dicerna to Report Third Quarter 2018 Financial Results and Host Conference Call on November 5, 2018
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2018 financial results after market close on Monday, November 5, 2018.
Oct 29, 2018 06:00 am ET
Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna's proprietary GalXC™ RNAi technology platform to progress new drug targets toward clinical development and commercialization. In addition, the partners will collaborate to move beyond the current techni
Oct 25, 2018 01:00 pm ET
Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the presentation of late-breaking data from its ongoing PHYOX Phase 1 trial, in which single-dose administration of DCR-PHXC, the Company’s lead GalXC™ product candidat
Oct 24, 2018 06:30 am ET
Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) t
Oct 23, 2018 08:25 am ET
New Research Coverage Highlights MEDIFAST INC, Palo Alto Networks, Salesforce, Agile Therapeutics, Dicerna Pharmaceuticals, and Corbus Pharmaceuticals — Consolidated Revenues, Company Growth, and Expe
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MEDIFAST INC (NYSE:MED), Palo Alto Networks, Inc. (NYSE:PANW),...
Oct 05, 2018 12:54 pm ET
Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that late-breaking data from the PHYOX Phase 1 trial of DCR-PHXC for the treatment of primary hyperoxaluria (PH) will be presented at the American Society of Nephrology
Sep 24, 2018 07:30 am ET
Dicerna to Participate in Two Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in October.
Sep 06, 2018 10:58 pm ET
Dicerna Announces Pricing of Follow-On Public Offering of Common Stock
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the pricing of its underwritten registered public offering of 7,680,492 shares of its common stock at a price to the public of $13.02 per share. Dicerna also granted the
Sep 05, 2018 04:01 pm ET
Dicerna Announces Proposed Follow-On Public Offering of Common Stock
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the commencement of a proposed underwritten registered public offering of 6,150,000 shares of its common stock. In connection with this offering, Dicerna expects to gra
Sep 05, 2018 06:05 am ET
Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced preliminary proof-of-concept data from its ongoing PHYOX Phase 1 clinical trial. A single-dose administration of DCR-PHXC, the Company’s lea
Aug 29, 2018 08:10 am ET
Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott — Fundamental Analysis, Key Performa
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Internap Corporation (NASDAQ:INAP), Approach Resources Inc. (NASDAQ:AREX),...
Aug 29, 2018 07:30 am ET
Dicerna to Participate in Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in September.
Aug 16, 2018 06:00 pm ET
Dicerna Strengthens Board of Directors with Two New Appointments
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointments of J. Kevin Buchi, former chief executive officer of Cephalon, Inc., and TetraLogic Pharmaceuticals Corp., and Cynthia Smith, former chief commercial off
Aug 08, 2018 04:05 pm ET
Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the second quarter ended June 30, 2018.
Aug 01, 2018 07:30 am ET
Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2018 financial results after market close on Wednesday, August 8, 2018.
Jul 25, 2018 08:20 am ET
Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community Bank System, Laboratory Corporation of America, and Dicerna Pharmaceuticals — Future Exp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearwater Paper Corporation (NYSE:CLW), Intercept Pharmaceuticals, Inc....
Jun 19, 2018 07:30 am ET
Dicerna Set to Join the Russell 3000® and Russell 2000® Indexes
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell US Inde
May 30, 2018 07:30 am ET
Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company has dosed the first primary hyperoxaluria (PH) patient with DCR-PHXC in the Group B portion of the PHYOX Phase 1 clinical trial. DCR-PHXC is an investiga
May 29, 2018 07:30 am ET
Dicerna to Present at the Jefferies 2018 Global Healthcare Conference
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate update at the Jefferies 2018 Global Healthcare Conference on Tuesday, J
May 18, 2018 07:55 am ET
Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR International, and Nordson with Renewed Outlook — Fundamental Analysis, Calculating Forward Move
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carolina Financial Corporation (NASDAQ:CARO), Dicerna Pharmaceuticals,...
May 14, 2018 04:05 pm ET
Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the first quarter ended March 31, 2018.
May 07, 2018 07:30 am ET
Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2018 financial results after market close on Monday, May 14, 2018.
Apr 20, 2018 12:13 pm ET
Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the company has resolved all litigation with
Apr 03, 2018 07:30 am ET
Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate update at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 10:15 a.m. CET. The conference will be held April 8-10, 2018 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Mar 23, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital — New Horizons, Emerging Trends, and Upco
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Goldfield Corp. (NYSE:GV), Dicerna Pharmaceuticals, Inc....
Mar 09, 2018 07:30 am ET
Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate overview at the B. Riley FBR Inaugural China Healthcare Investing & Part
Mar 08, 2018 04:05 pm ET
Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2017.
Mar 05, 2018 07:30 am ET
Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 201
Mar 01, 2018 07:30 am ET
Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2017 financial results after market close on Thursday, March 8, 2018.
Feb 06, 2018 07:30 am ET
Dicerna to Participate in Upcoming Investor Conferences
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences.
Jan 24, 2018 07:30 am ET
Analysis: Positioning to Benefit within Ferroglobe, Corbus Pharmaceuticals, Meritage, Dicerna Pharmaceuticals, Castle Brands, and Ply Gem — Research Highlights Growth, Revenue, and Consolidated Result
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe PLC (NASDAQ:GSM), Corbus Pharmaceuticals Holdings,...
Jan 23, 2018 07:30 am ET
Dicerna to Present at Noble Capital Markets’ NobleCon14
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference on Tues
Dec 14, 2017 09:29 am ET
Dicerna Announces Pricing of Follow-On Public Offering of Common Stock
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (“Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the pricing of its underwritten registered public offering of 5,714,286 shares of its common stock at a price to the public of $7.00 per share. Dicerna also
Dec 13, 2017 04:45 pm ET
Dicerna Announces Proposed Public Offering of Common Stock
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (“Dicerna” or the “Company”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the commencement of a proposed underwritten public offering of shares of its common stock (“Common Stock”). The

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.